Evidence map›Paper›PMID 42230636›Full record

ArticleNature communications2026

A tunable Cas12a platform for single-cell perturbation screening and CRISPRi.

Valentina Snetkova, Carolina Galan, Romain Lopez, Antonio R Rios, Takamasa Kudo, Kristel Dorighi, Søren Warming, Benjamin J Haley

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Valentina SnetkovaGenentech, Inc, 1 DNA Way, South San Francisco, CA, USA.
Carolina GalanGenentech, Inc, 1 DNA Way, South San Francisco, CA, USA.
Romain LopezGenentech, Inc, 1 DNA Way, South San Francisco, CA, USA.
Antonio R RiosGenentech, Inc, 1 DNA Way, South San Francisco, CA, USA.
Takamasa KudoGenentech, Inc, 1 DNA Way, South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9709-5549
Kristel DorighiGenentech, Inc, 1 DNA Way, South San Francisco, CA, USA.ORCID http://orcid.org/0009-0002-7695-572X
Søren WarmingGenentech, Inc, 1 DNA Way, South San Francisco, CA, USA. sorenw@gene.com.ORCID http://orcid.org/0000-0002-5721-0741
Benjamin J HaleyGenentech, Inc, 1 DNA Way, South San Francisco, CA, USA. benjamin.haley@umontreal.ca.ORCID http://orcid.org/0000-0002-0074-0020

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-cell perturbation (Perturb-seq) screens have primarily relied on Cas9 for inducing loss-of-function phenotypes, whereas Cas12a, despite its unique effectiveness for multiplex guide expression, remains underexplored. This may be due to Cas12a's guide RNA array (pre-crRNA) self-processing activity and the subsequent challenges associated with pre-crRNA sequence recovery during single-cell RNA sequencing library preparation. To overcome the self-processing constraint, we optimized pre-crRNA expression vectors and established a degron-based, enhanced Cas12a system for gene knock-out. As demonstrated across cell types, target genes, and with a minimized guide RNA library, this platform allows for accurate detection of pre-crRNAs and gene editing-induced effects on the transcriptome in single cells. Additionally, we show that HyperLbCas12a outperforms other existing variants for multiplexed gene suppression. While the rapid reversibility of this repressor highlights specific kinetic constraints for degron-based single-cell recording, the system provides a potent, modular tool for contexts requiring tunable, transient silencing. Together, this suite of technologies greatly expands the possibilities for future Perturb-seq efforts and broader application of Cas12a for genetic disruption at scale.

Indexed as

Bacterial ProteinsCRISPR-Associated ProteinsCRISPR-Cas SystemsGene EditingSingle-Cell AnalysisAnimalsDegronsEndodeoxyribonucleasesGene Knockout TechniquesHEK293 CellsHumansRNA, Guide, CRISPR-Cas SystemsSingle-Cell Gene Expression AnalysisTranscriptomeBacterial ProteinsCas12a proteinCRISPR-Associated ProteinsEndodeoxyribonucleasesRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID42230636
PMCPMC13392366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.